

RESEARCH ARTICLE

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *RSC Med. Chem.*, 2025, 16, 2819

VHL-independent degradation of hepatitis B virus e antigen (HBeAg) by VHL-binding chimeric small molecules†

Liam T. Hales, ^{‡a} Simon J. Mountford, ^a Mina Takawy, ^b Danni Colledge,^b Belinda Maher, ^{cd} Jake Shortt,^{cde} Philip E. Thompson, ^{★a} Sam A. Greenall ^{★c} and Nadia Warner^{★b}

Hepatitis B virus (HBV) is a leading cause of liver cancer worldwide, with current treatment options unable to provide lasting efficacy against chronic infection. A key viral protein, HBV e antigen (HBeAg), plays an important role in suppressing the cellular and humoral immune response during infection and its loss is a precursor to clearance of chronic HBV infection. Its structural similarity to capsid forming HBV core protein antigen (HBcAg) makes it an intriguing, yet understudied target for pharmaceutical intervention. Recently, targeted protein degradation has been successfully applied against several viral proteins. This work investigates the targeting of HBeAg using heterobifunctional degraders derived from reported HBcAg ligands known to interact with HBeAg. Multiple compounds designed to recruit the VHL E3 ligase were found to be capable of reducing recombinant HBeAg protein levels in a HiBiT reporter assay system. Surprisingly, this decrease was found to be independent of VHL recruitment but driven by structural motifs of the VHL recruiting ligand, VH032. Virological assessment of these compounds against wildtype virus revealed an equipotent capability to reduce secreted HBeAg compared to the parental inhibitor, however increased efficacy was observed against an inhibitor resistant strain. Together, this work provides an initial description of the feasibility of converting HBV capsid-targeting ligands into degraders and provides evidence that such degraders may harbour improved activity against mutated forms of target which are resistant to parental compounds.

Received 6th February 2025,
Accepted 22nd March 2025

DOI: 10.1039/d5md00118h

rsc.li/medchem

Introduction

Hepatitis B virus (HBV) infection is a global health issue. Of particular concern is chronic HBV infection (CHB) due to the severe damage that ongoing infection and inflammation causes to the liver, often leading to liver cirrhosis and hepatocellular carcinoma (HCC). According the WHO's 2017

Global Hepatitis report, 257 million people live with CHB, with the disease especially prevalent in the African and Western Pacific regions.¹

HBV DNA is transcribed into four mRNAs which code for seven key proteins involved in the HBV infection and replication cycle: three HBV surface antigens (HBsAg), HBV X protein (HBx), viral DNA polymerase (Pol), HBV core protein antigen (HBcAg) and HBV e protein (HBe). While current treatment options targeting these proteins exist, such as the nucleos(t)ide Pol inhibitors, latent reservoirs of HBV covalent closed circle DNA (cccDNA) lead to viral rebound following withdrawal of treatment.²

Drugs that target the closely related HBcAg and HBeAg are of particular interest. Despite the functional differences of these proteins, they are structurally similar. The HBcAg forms the icosahedral nucleocapsid, predominantly *via* the oligomerisation of 120 sets of HBcAg dimers.³ After packaging the pre-genomic RNA fused to Pol, the mature nucleocapsid is coated with envelope protein, then secreted as a virion, highlighting the essential role HBcAg plays in viral replication. Mature nucleocapsids can also enter the nucleus and refill the pool of cccDNA, implicating HBcAg in maintenance of HBV

^a Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Australia. E-mail: philip.thompson@monash.edu^b Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at The Peter Doherty, Institute for Infection and Immunity, Melbourne, 3000, Australia. E-mail: nadia.warner@vidri.org.au^c Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 3168, Australia. E-mail: sameer.greenall@monash.edu^d Monash Haematology, Monash Health, Clayton, 3168, Australia^e Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5md00118h>

‡ Current address: MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.

infection.⁴ HBeAg differs from HBcAg by a 10 amino acid N-terminal sequence leader sequence. This sequence directs the protein to the Golgi apparatus,⁵ preparing HBeAg for secretion by inducing an alternate dimerization mode compared to HBcAg, which allows for the secretion of HBeAg.^{6–8}

HBeAg secretion has been shown to disrupt the humoral immune response, including pathogen recognition and cytokine production.^{9,10} Evidence has also suggested that HBeAg functions as a tolerogen for immune T-cells,^{11,12} acting as a “decoy” protein to reduce the immune response toward the nucleocapsids, composed of antigenically similar HBcAg.¹³ This tolerogenic role, along with the aforementioned interactions with various immune signalling pathways, suggest that successful removal of HBeAg from systemic circulation may aid the humoral immune response to infection.

HBeAg and its precursors (p25 and p22) are also partially retained intracellularly.^{14–16} Here they contribute to dampening of the local hepatocyte immune response and inhibit apoptosis pathways responsible for hepatocyte death during HBV infection.^{10,17} In this way, HBeAg contributes to the survival of these infected cells, promoting viral replication and chronic infection. HBeAg has also been linked to the pathogenesis of HCC through upregulation of miR-106b, a protein known to accelerate cell-cycle progression and increase cell proliferation in hepatocytes.^{10,18} HBeAg is produced during chronic HBV infection, however can be lost in later stages of infection. HBeAg-negative individuals are more likely to progress to HBsAg loss and eventual functional cure of HBV infection. Loss of HBeAg could therefore be considered an important precursor for clearance of HBV.¹⁹

HBcAg has been targeted using a class of small molecules termed core protein allosteric modulators (CpAMs). The heteroaryldihydropyrimidine (HAP) chemotype has had particular success with multiple examples having entered clinical trials.²⁰ This class of HBV inhibitors work by altering the kinetics of capsid assembly, with the increased rate leading to the formation of aberrant capsids or non-capsid polymers.²¹ These proteins are then degraded *via* the macroautophagy-lysosomal pathway.^{22,23} Interestingly, HAP CpAMs have also been shown to reduce secreted HBeAg in cell and mouse models and cause an accumulation of precore proteins in the nucleus.²⁴

Over the last decade, small molecule degraders of disease-causing proteins have risen to the forefront of drug discovery.²⁵ These molecules have predominantly fallen into the categories of proteolysis targeting chimeras (PROTACs) or molecular glues.²⁶ Both compound classes function by manipulating the ubiquitin proteasome system (UPS), inducing proximity between an E3 ubiquitin ligase (E3L) and a target protein, facilitating the ubiquitination of the protein of interest, and signalling it for degradation *via* the proteasome.²⁷ Recently, additional classes of small molecule degraders have emerged, including hydrophobic tagged (HyT) degraders, which initiate the protein quality control response (PQR) within the cell.²⁸

While oncological protein targets have dominated the literature to-date, the same advantages in efficacy and specificity

associated with targeted protein degradation (TPD) have also encouraged application of this approach in the pursuit of antivirals. Examples include degraders against SARS-CoV-2, hepatitis C virus (HCV), human immunodeficiency virus (HIV) and dengue virus.^{29–34} Several of these studies have also suggested that TPD can generate additional efficacy against drug resistant strains of virus.^{30–32}

The progression of HBV infection is reliant upon HBeAg due to a combination of its intracellular function and the humoral effects of the secreted portion. Abrogation of both sets of effect is highly desirable, making it an attractive target for degradation *via* the TPD approach. Successful degradation of HBeAg and reduction of its immunosuppressive effects, described above, may restore the ability of the infected cell, tissue, or body to combat viral infection. Additionally, due to the structural similarity of HBeAg and HBcAg, HAP-based degraders could engage both HBcAg and HBeAg,²⁴ potentially enabling successful small molecule induced degradation of both proteins. This may result in an enhanced antiviral effect with potential to overcome issues with drug resistance exhibited by the antiviral drugs from which these degraders are derived.²⁹

Here, we have described the elaboration of HAP HBV inhibitor NVR-010-001-E2,³⁵ into bifunctional compounds containing E3L-recruiting moieties. Biochemical testing of these compounds in a HiBiT tagged HBeAg cell model revealed that several VHL-recruiting compounds caused the anticipated reductions in secreted HBeAg. Notably, we observed that these compounds sharply decreased intracellular HBeAg levels, in contrast to treatment with the parental inhibitor. We determined that degradation was largely VHL-independent using pharmacological and genetic controls. Next, we prepared analogues bearing hydrophobic tags and truncated VHL-recruiting scaffolds, with our results suggesting that a hydrophobic tag mechanism may be responsible for the observed degradation. Finally, using a transfected model of viral infection, we demonstrated that compound **LH-3** and its *cis* epimer were active in reducing HBeAg secretion from wild-type HBV to a comparable level to the parental inhibitor, and exhibited superior activity in preventing HBeAg secretion from a HAP-resistant strain of HBV.

Results

Design and synthesis of degrader candidates

We began by designing a screening set of PROTAC-like compounds linked to the HAP scaffold after inspection of the co-crystal structure of HBcAg and inhibitor NVR-010-001-E2 (Fig. 1A).³⁵ Analysis of this structure revealed a solvent exposed morpholine group (Fig. 1B), which had been adapted to piperazine for the inclusion of fluorophores (Fig. 1C),³⁶ or substituted in second and third generation HBV inhibitors without interrupting essential binding interactions.^{37,38} A variety of alkyl and PEG linkers with high flexibility and diverse length were selected to aid in determining the ideal distance between the two recruiting elements (Fig. 2A).




Fig. 1 A. Crystal structure of NVR-010-001-E2 bound to HBeAg N-domain (Y132A mutant, PDB: 5E01³⁵), B. Structure of second-generation HAP, NVR-010-001-E2, C. Structure of fluorophore-linked HAP, HAP-ALEX.³⁶

The compounds were prepared by adaptation of literature procedures from the commercially available starting material (Scheme 1). Bromination yielded key intermediate, **1**,³⁸ followed by the installation of various heterocycles *via* nucleophilic substitution to generate parental inhibitor and reference compound, **2** along with key intermediates. Full details are provided in the ESI.†

E3 ligase recruiter (E3R)-linker conjugates were prepared with carboxylate, piperazinyl, azido or amino terminal functionality (ESI,† Schemes S2–S8). Three E3R ligands were selected for incorporation into the initial series of degrader candidates. Canonical VHL-recruiter, VH032, was coupled with linkers *via* the terminal amine of the *tert*-leucine residue. To recruit CRBN we utilised 4-hydroxythalidomide, pomalidomide (Pom) or DGY- a ligand which has been previously used to develop Hepatitis C virus targeting PROTACs.³¹ Various strategies were employed to prepare the final degrader candidates including amide or urea coupling, Cu(i)-catalysed azide-alkyne cycloaddition (CuAAC) or nucleophilic substitution. Collectively, 13 candidate compounds were prepared, spanning three E3Rs and including linkers ranging from 2 to 14 heavy atoms (Fig. 2A).

Biochemical assessment of HBeAg levels using a HiBiT assay system

To assay HBeAg levels following treatment with degrader candidates, a HEK293T cell line with doxycycline (DOX) inducible HiBiT-tagged HBeAg expression was established. This

assay format has been widely used in degrader development to assess protein levels in both cell lysate and live cells.^{39–42} Two cell lines were developed to enable the assessment of the compounds in two ways. Both contained the appropriate C-terminal deletion to match the sequence of endogenously secreted HBeAg, however the first non-secretory cell line, HEK293T^{HiBiT-HBeAg-NS}, lacked the N-terminal leader sequence required for secretion of HBeAg.¹⁴ In doing so, compounds were assessed for their holistic effect on HBeAg levels, rather than differentiating between secreted and intracellular levels of HBeAg. A second secretory construct, HEK293T^{HiBiT-HBeAg-S}, contained the N-terminal leader sequence required for secretion, enabling differentiation between intracellular and secreted HBeAg levels.

Compounds were first assessed using the HiBiT assay. The non-secretory HEK293T^{HiBiT-HBeAg-NS} cell line was treated with each test compound at 10 μ M for 24 h and then subjected to a Nano-Glo HiBiT lytic detection assay with no washout of the media, providing a measure of total luminescence (Fig. 2B). A no DOX control group was included to ensure luminescence was a result of DOX induced HiBiT-HBeAg expression.

Compared to the parental inhibitor **2**, several candidates demonstrated a significant ($P \leq 0.001$) reduction in luminescence. Corresponding to a reduction in total HiBiT-HBeAg-NS protein. VH032-linked compounds **LH-1**, **LH-2**, **LH-3** and **LH-6** appeared to be the most active, reducing HBeAg levels to less than 30% of the DMSO control. As expected, the parental inhibitor **2** caused an overall reduction of HBeAg consistent with literature reports (59% of control




Fig. 2 A. Chemical structure of degrader candidates, composed of a heteroaryldihydropyridine (HAP) HBeAg recruiting domain, varied linkers, and one of three E3L recruiters. B. HEK293T^{HiBiT-HBeAg-NS} cells were treated with candidates at 10 μM for 24 h, then luminescence detected and normalised to the DMSO control. Compounds with a statistically significant increase in potency compared to parental compound 2 are marked, where **** represents $P < 0.0001$, *** $P \leq 0.001$, as determined by one-way ANOVA. C. A matched ViaLight™ assay was performed to determine the effect of treatment on cell viability.


levels).²⁴ CRBN recruiting compounds were notably less active, indicating a preference for the VHL-recruiting scaffold. Interestingly, **SM-3**, and more markedly **SM-4**, caused an accumulation of total HBeAg, potentially indicating stabilisation of the protein. Note that a matched ViaLight™ assay showed no evidence of compound cytotoxicity (Fig. 2C).

Of the most active molecules, there was no apparent pattern in terms of linker composition. **LH-2** and **LH-3** represent members of a sub-series defined by amide coupling between an alkyl linker and the piperazine of the HAP component and differ by two linker carbons. Compounds **LH-1** and **LH-6** were prepared by amine alkylation resulting in a tertiary amine linkage motif, however **LH-1** contains a minimal methylene linker, while **LH-6** contains an additional triazole ring and a hexyl linker.

We next used the secretory HEK293T^{HiBiT-HBeAg-S} cell line to assess secreted and intracellular HBeAg using **LH-1** and **LH-3**. The two protein populations were determined by

extracting the cell media present during drug treatment from the cells after 24 h and reading the luminescence signal for secreted HBeAg. The cells were then washed with fresh media (to remove trace amounts of secreted HBeAg) and assayed separately using a lytic HiBiT assay for determination of intracellular HBeAg.

These assays revealed a markedly different phenotypic response to **LH-3** compared to parental HAP compound 2. While both treatments decreased levels of secreted HBeAg in a concentration dependent manner (<7% of DMSO at 20 μM), the effect of the two compounds on intracellular HBeAg levels was markedly different (Fig. 3A). While treatment with 2 caused an accumulation of intracellular HBeAg, **LH-3** caused a significant reduction in intracellular HBeAg at concentrations above 1 μM, with luminescence reduced to 46% of the untreated control at 20 μM (Fig. 3A). Both treatments decreased levels of secreted HBeAg in a concentration dependent manner (<7% of DMSO at 20 μM)



Scheme 1 Synthesis of key HAP intermediates and initial series of HBeAg degrader candidates. a) *N*-Bromosuccinimide, DCM, r.t., 1 h, 64%, b) morpholine, MeOH, 3 h, r.t., 40%.

The same trend was observed for related compound **LH-1** (Fig. S1†).

Given that these compounds were all designed to recruit VHL we aimed to assess if the reduction in HBeAg levels caused by **LH-1** and **LH-3** was due to VHL-dependent proteasomal

degradation. We therefore conducted parallel experiments using negative control compounds *cis***LH-1** and *cis***LH-3** alongside **LH-3** and **LH-1** (Fig. 3B). If a VHL-dependent PROTAC-like mechanism was responsible for degradation of HBeAg, treatment with *cis* compounds should cause a substantial




Fig. 3 A. HEK293T^{HiBiT-HBeAg-S} cells were titrated with compounds **2** and **LH-3** for a 24 h treatment period. B. The HEK293T^{HiBiT-HBeAg-S} cell line was treated with compounds **2**, **LH-1**, *cis***LH-1**, **LH-3** and *cis***LH-3** at 10 μ M for 24 h. C. Regular or VHL KO HEK293T^{HiBiT-HBeAg-S} cell lines were treated with compounds **2**, **LH-1** or **LH-3** at 10 μ M for 24 h. Secreted HBeAg levels were reduced in all treatment groups, with minimal difference observed between cell lines. VHL KO was also unable to rescue intracellular HBeAg levels. **** represents $P < 0.0001$, *** $P \leq 0.001$, ** $P \leq 0.01$, * $P \leq 0.05$, ns = $P > 0.05$ as determined by one-way ANOVA.

reduction in activity compared to the *trans* counterparts. At 10 μM , the negative control compounds both showed a slightly reduced ability to reduce secreted HBeAg compared to their *trans* counterparts (**LH-1** vs. **cisLH-1**, 7% vs. 31% and **LH-3** vs. **cisLH-3**, 7% vs. 20%, $P < 0.0001$), indicating some contribution from VHL recruitment.

Intracellular HBeAg levels were only modestly affected with the *cis* compounds. The **LH-1/cisLH-1** pair exhibited a small decrease in activity (48% vs. 59%, $P = 0.006$), while the difference between the **LH-1/cisLH-3** pair (44% vs. 38%, $P = 0.135$) was not significant. We confirmed abrogation of VHL binding by immunoblotting where **LH-1** and **LH-3** exhibited stabilisation of VHL while the *cis* epimers did not (Fig. S2†). These results suggested that while a PROTAC-like mechanism may have a minor contribution to the reduction of intracellular HBeAg, the primary mechanism of degradation is independent of VHL recruitment.

For further confirmation, a VHL knockout (KO) cell line (HEK293T^{VHL KO} HiBiT-HBeAg-S) was generated for use in the HiBiT assay. Treating these two cell lines with compounds **2**, **LH-1** and **LH-3** revealed a similar trend to the investigation of the *cis/trans* pairs. We compared the VHL-expressing cell line to VHL KO cells by HiBiT assay (Fig. 3C) which were further confirmed by western blot (Fig. S3B and C†). There was no significant difference in secreted HBeAg levels between treatment groups following incubation with 10 μM of **2** (7% vs. 10%). **LH-1** (20% vs. 32%, $P < 0.0001$) and **LH-3** (7% vs. 12% $P = 0.0177$) showed statistically significant, albeit minor, rescue of secreted HBeAg levels. We were again interested in intracellular HBeAg levels, which increased in all treatment groups when moving from the parental HEK293T^{HiBiT-HBeAg-S} to the VHL KO cell line (**2**: 116% vs. 144% $P < 0.0001$, **LH-1**: 38% vs. 50% $P = 0.0074$, **LH-3**: 44% vs. 56% $P = 0.0126$). This increase in luminescence for all drug treatment groups (including parental compound **2**) potentially indicates a general VHL-dependent depletion of HBeAg, rather than a true dependence on VHL recruitment for the mechanism of **LH-1/LH-3** induced HBeAg degradation.

Together, these data obtained through chemical and biological interrogation indicate that despite being designed to recruit VHL, the observed degradation of HBeAg induced by **LH-1** and **LH-3** is both largely independent of VHL, yet distinct from the activity of the HAP parental inhibitor, **2**. We attempted to probe the role of the proteasome and Cullin-RING E3 ligase activation on the observed degradation of HBeAg *via* co-administration of **LH-3** with proteasome inhibitor bortezomib and neddylation inhibitor MLN4924. Unfortunately, these treatments at typically used concentrations (bortezomib: 10 nM, MLN4924: 500 nM) led to reduced cell viability over the 24 h incubation, which confounded attempts to measure reversal of proteasome dependent degradation.

Preparation and assessment of truncated LH-3 derivatives


Having established that **LH-1** and **LH-3** function *via* a largely VHL-independent mechanism, we next investigated the

molecular features responsible for degradation to aid in determining mechanism. Structurally, parental inhibitor **2** and **LH-1/LH-3** differ by the addition of a linker and the VH032 motif yet have markedly different effects on intracellular HBeAg levels. Therefore, to determine the important moieties for this effect, we prepared a series of compounds in which the VHL-recruiting scaffold of **LH-3** is truncated at five locations or replaced with an alternative E3 ligase recruiter (Fig. 4A). This included the consecutive removal of the 4-methylthiazole, benzylamine, *trans*-hydroxyproline and *tert*-leucine motifs to give **LH-3-T1**, **LH-3-T2**, **LH-3-T3**, **LH-3-T4** respectively. Additionally, a *des*-hydroxy variant, **LH-3-desHyd**, was prepared where proline replaced *trans*-hydroxyproline, and **LH-3-Pom**, which replaced the VHL-recruiter with cereblon-recruiter, pomalidomide. These compounds were prepared in analogous fashion to **LH-3**, but also included solid-phase synthesis routes in some examples (see ESI† Fig. S5).⁴³

The truncated derivatives of **LH-3** were assessed in the HiBiT assay at 10 μM (Fig. 4B). **LH-3-T1** (16%) and **LH-3-desHyd** (3%) reduced secreted HBeAg to similar levels as **LH-3** (8%). Other derivatives caused a more modest reduction in HBeAg, with **LH-3-T2** (80%) exhibiting the most dramatic reduction in potency compared to **LH-3**.

Monitoring intracellular levels of HBeAg following compounds treatment revealed key motifs within the VH032 scaffold (Fig. 4C). **LH-3-desHyd** (20%) exhibited an apparent improvement in activity compared to **LH-3** (44%) despite it lacking the hydroxyl group essential for VHL binding. However, this compound also exhibited some cytotoxicity at 10 μM in the parallel ViaLight® assay (Fig. S4†). Further analysis illustrated that extensive truncations caused the compounds to shift from reducing intracellular HBeAg levels, to causing an accumulation, closer to the effect of a HAP inhibitor such as **2**. This is particularly evident when **LH-3-T1** (active, 62% of DMSO levels) and **LH-3-T2** (inactive, 97% of DMSO levels) are compared.

These data indicated that the full VH032 moiety is not entirely essential for activity, but drastic alteration hinders the ability of these compounds to act as HBeAg degraders. **LH-3-T1** retained activity in both assays, revealing that the 4-methylthiazole is not required for the novel intracellular degradation mechanism or for inhibition of HBeAg secretion. In contrast, removal of the benzylamine group and subsequent truncations reduced the potency of the compounds as inhibitors of HBeAg secretion and caused the compounds to exhibit limited effect on intracellular HBeAg. Treatment with **LH-3-T3** (115%) and **LH-3-T4** (122%) led to an accumulation of intracellular HBeAg compared to control level, similar to the phenotype observed for cells treated with the parental compound in previous assays (see Fig. 3). In this way, truncates **LH-3-T2**, **LH-3-T3** and **LH-3-T4**, which failed to reduce intracellular HBeAg levels, can be considered HAP compounds with reduced potency, rather than HBeAg degraders. Therefore, it is the properties of the 4-methylthiazole and benzyl group which seem to be important for this mechanistic switch. Interestingly, **LH-3-**



Assessment of intracellular HBeAg levels revealed that the HyT analogues were less potent than **LH-3** (Fig. 5C). Consistent with previous assays, at 10 μ M **LH-3** reduced intracellular levels to 45% of control. In comparison, the activity of **LH-3-adam** (93%) and **LH-3-menth** (77%) was significantly reduced, while **LH-3-fluor** (110%) caused an accumulation of HBeAg. These results suggest that certain properties of the VH032 scaffold are more suited inducing HBeAg degradation than any of the selected HyTs. However, the reduction of intracellular HBeAg by **LH-3-menth** demonstrates that it is possible to replicate the **LH-3** intracellular HBeAg depletion phenotype by replacing the VH032 moiety with a HyT. This provides preliminary evidence for HyT-induced degradation, however further work is required to confirm the mechanism responsible.

Following incubation with parental HAP inhibitor, **2**, lead compound **LH-3**, or control compounds *cis***LH-3** at 10 μ M for




Fig. 6 Virological assessment of degrader candidates. **A.** HepAD38 cells treated with compounds at 10 μ M for 6 days before removal of media and western blot analysis of cell lysate using anti-core protein antibody. **B.** Antiviral activity of LH-3/*cis*LH-3 was assessed in Huh7 cells transfected with either WT or T109I mutant strain of HBV. The cells were treated with compound at 10 μ M for 24 h and media levels of HBeAg quantified. * $P \leq 0.05$, ns = $P > 0.05$ as determined by two-way ANOVA.

24 h, secreted HBeAg levels were assessed using the Diasorin Liaison® system. The collected data is summarised in Fig. 6B and highlights the following key findings. Treatment of the WT expressing cells with both **2** and **LH-3** decreased secreted HBeAg levels to ~8% of the untreated levels, indicating that **LH-3** is effective at curtailing virally produced WT HBeAg, supporting our findings from the transfected HiBiT screening cell line.

When considering the T109I mutant HBV **LH-3** demonstrated increased efficacy compared to the parental inhibitor. As anticipated, given the resistance mutation, the efficacy of **2** was reduced by 2 to 3-fold when moving from WT to resistant strain (8% vs. 23.5% $\pm$ 5.5) which was significantly inferior to its activity against WT strain ($P = 0.0438$). In comparison, heterobifunctional compound **LH-3** reduced HBeAg secretion to a similar extent to the WT transfection model (11.5% $\pm$ 1.5). These data suggest that the conversion of **2** into a bifunctional molecule imparts increased efficacy against a HAP resistant strain of HBV.

Treatment of WT HBV expressing cells with *cis***LH-3** reduced HBeAg secretion to 17.5% $\pm$ 4.5 as compared to **LH-3** (8.5% $\pm$ 1.5). This is consistent with the trend observed during HiBiT assay assessment where activity against secreted HBeAg is reduced, but not lost, upon inverting the stereochemistry of the hydroxyproline residue (see Fig. 3C). This indicates that the antiviral activity of **LH-3** may be partially reliant on VHL binding. In the resistant T109I expressing cells *cis***LH-3** reduced HBeAg secretion to ~22%, which was not significantly different to the activity against the WT group, providing evidence that the VHL-independent degrader activity was also crucial to maintaining activity against the mutated T109I target.

Discussion

The work presented here describes the identification of PROTAC-like molecules capable of degrading HBeAg, an important HBV protein. These compounds were derived from

a HAP scaffold closely related to preclinical inhibitor NVR-010-001-E2 and display an interesting and diverse set of phenotypes across both transfected and viral infection models.

Biochemical testing using a transfected HiBiT reporter system enabled rapid assessment of both secreted and intracellular HBeAg levels following drug treatment, which facilitated the identification of multiple candidates, including **LH-1** and **LH-3**, capable of reducing HBeAg levels in a distinct manner from the parental inhibitor, presumably *via* the degradation of HBeAg. Following the application of negative control compounds and a VHL KO cell line, we were particularly surprised to observe that HBeAg degradation was largely VHL-independent, despite designing the compounds to recruit VHL.

These findings serve to highlight the importance of a thorough investigation of the mechanism unpinning observed degradation. This has become an increasingly important discussion in the PROTAC literature due to a notable report of an unexpected E3L being responsible for degradation,⁴⁶ and the appearance of false positives due to secondary cellular effects or assay artefacts.⁴⁷

While an unexpected mechanism of degradation has been reported for a PROTAC recruiting the aryl hydrocarbon receptor (AhR),⁴⁸ to our knowledge, our findings represent the first report of a VHL-independent degrader designed to recruit VHL. Given the wide range of proteins targeted using this approach, this finding is of note and raises the question of how many other reported degraders are acting in unexpected ways. Our investigation into the role of the structural motifs present within the VHL recruiting domain demonstrated the importance of the hydrophobic *para*-benzylamine for the observed degradation. Given the abundance of this functionality in VHL-recruiting PROTACs, it is possible that it may be a contributing factor to other successful degraders. The installation of known hydrophobic tags generated compounds **LH-3-menth** and **LH-3-adam** capable of recapitulating the effects of **LH-3**, albeit less potently. Thus, if **LH-3** is facilitating

degradation *via* a HyT mechanism, it appears that compared to the HyTs utilised, the structure of the VHL recruiting moiety is more appropriately configured to initiate misfolding and induce the PQR mechanism responsible for HyT-mediated degradation. It is also important to acknowledge that the data presented here does not consider the effect of the modifications on factors such as cell permeability or target occupancy. Consequently, it is difficult to entirely resolve the intricacies of the structure–activity relationship of the VH032 or HyT modifications.

Alongside understanding the important structural motifs, it is crucial to more extensively investigate the cellular pathways involved in degradation, particularly those involving the proteasome. Attempts to probe this pathway using standard methods such as administration of test compounds with proteasome inhibitor bortezomib and neddylation inhibitor MLN4924 were inconclusive due to interference with the transfection system as compared to reported mammalian constructs.^{49,50} We had similar experience with HiBiT-Mpro constructs.⁴² Other strategies using an alternate experimental set up may be necessary to study these processes. One previously successful approach involved a CRISPR-Cas9 screen of gene dependency during the identification of DCAF16 as the E3L responsible for the activity of a bivalent molecular glue.⁴⁶ A similar strategy could be utilised here to specifically probe the role of Cullin-RING E3L in the observed degradation. Any advances made towards identifying key proteins will serve to improve understanding of this system, as well as additional forms of degradation, HyT-driven or otherwise.

Assessment of these compounds in cellular HBV infection models confirmed activity of the heterobifunctional compounds against virally produced protein. Application of viral infection models is crucial and differs from the HiBiT reporter assay for several reasons. We firstly note that HBeAg was the primary target in this investigation and the sole overexpressed viral protein in the transfected cells. In the viral infection cellular context, the ligand would be expected to bind both HBeAg and HBcAg and exert its antiviral effect through a binary mechanism including the disruption of capsid formation. As a result, there is an expected background level of antiviral activity which contributes to a reduction in overall protein levels, including HBeAg. Second, it would be expected that the different compound structures with modified linkers are likely to have different affinities for the various protein forms, hence exhibit varied levels of background antiviral activity. Third, the assays are conducted over 6 days, allowing for a more pronounced effect of protein turnover (synthesis, secretion and degradation) than in the 24 h treatment of the transfection model.

Through immunoblotting we were able to assess HBcAg levels and confirmed activity of **LH-3** and *cis***LH-3** against core protein albeit less effectively than the parental compound. Unfortunately, the assay format failed to detect HBeAg levels due to a lack of sensitivity. However, upon moving to a more sensitive assay format, we demonstrated that **LH-3** shows a unique antiviral phenotype against a HAP resistant strain of

HBV. The consistent efficacy of **LH-3** across the WT and HAP-resistant HBV strains suggests that the binding affinity of the HAP component of the molecule may be less crucial to its efficacy than for the parental HAP compound. This feature could be attributed to the TPD mechanism where PROTACs and other heterobifunctional degraders are less reliant on tight binding to their target, due to their catalytic mechanism of degradation.⁵¹ Harnessing these benefits by further optimising anti-HBV degraders is therefore an attractive option in efforts to overcome drug resistant strains of the virus.

A TPD approach to the treatment of HBV infection is an exciting, yet underexplored field of research, with this study serving as the first report of small-molecule degrader of HBeAg, albeit one which functions *via* an ambiguous mechanism. When considering this unexpected mechanism, this work also highlights the complexity of TPD, particularly in the field of antiviral drug discovery. Additionally, the data presented here contributes evidence to the growing body of work that indicates targeted degraders of viral proteins have additional antiviral benefits over the parental compound. While significant optimisation and mechanistic investigation is required to develop a potent degrader of HBeAg, we are encouraged to continue investigating protein degraders of HBeAg along with other viral protein targets.

Methods

Synthetic chemistry

Full details can be found in the ESI.†

Computational determination of log *P*

The SMILES strings of the compounds of interest were input into the Swiss ADME Web tool (<https://www.swissadme.ch/>) and results exported.⁴⁴ The consensus log *P* values were collated and compared.

Cell line generation

HEK293T VHL KO cell line. HEK293T cells (purchased from ATCC and verified by STR profiling) were transfected with pX458 plasmid containing sgRNA targeting VHL (DOI: <https://doi.org/10.1126/sciadv.abm6638>) using Fugene 6 (3 : 1, Fugene : DNA) and grown for 72 h before flow cytometry sorting of the eGFP expressing cell population. After cell recovery and expansion, cells were frozen for archive and passaged for HBeAg-HiBiT reporter cell line generation. Loss of VHL target was verified by Western blotting *vs.* HEK293T parental cells using an anti-VHL rabbit polyclonal antibody (Cell Signaling).

HEK HBeAg reporter cell line. The nucleotide sequence for the appropriate HBeAg construct was amplified by PCR with a reverse primer incorporating the HiBiT tag sequence for addition to the 3' end. The PCR product was then cloned into the pLVX-TetON-PuroR lentiviral vector (Takeda) and insertion verified by EcoRI/BamHI restriction digest and

subsequent sequencing of the insert. Lentiviral generation was then performed in HEK293T cells by transfection in PEI of the pLVX-TetON-HiBiT-HBeAg-NS-PuroR or pLVX-TetON-HiBiT-HBeAg-S-PuroR vector plasmids along with the 2nd generation packaging plasmids pVSVg and pPAX2. Lentiviral supernatants, harvested at 48 h and 72 h post transfection, filtered through a 0.45 μm filter, pooled and then used to infect HEK293T cells (for the parental HEK293T cell background) or HEK293T VHL KO cells (for VHL KO background) for 24 h in the presence of 5 $\mu\text{g mL}^{-1}$ of polybrene. The next day, virus was removed and cells washed once in PBS before being lifted in Accutase and then replated in DMEM + 10% FBS media supplemented with 2 $\mu\text{g mL}^{-1}$ of puromycin for selection. After selection and expansion, cells were frozen for stocks and passaged for subsequent testing.

HiBiT assay

For DOX induction of target and monitoring degrader activity against secreted HBeAg target by HiBiT assay, 96 well white wall plates were seeded with 20 000 cells per well in triplicate overnight. The next day, various concentrations of DOX were added and cells incubated for 24 hours at 37 °C (for degrader treatments – degraders were added at the same time as DOX induction and then incubated for another 24 h to degrade target). The next day, 50 μL of media per well was removed and transferred to a fresh white walled 96-well plate and were subjected to a Nano-Glo® HiBiT Extracellular Detection System assay as per manufacturer's instructions. In the source plate, the remaining media was removed and wells carefully washed once in DMEM + 10% FBS before a fresh 50 μL of media was then added back in – the level of intracellular HBeAg was then measured using the Nano-Glo® HiBiT Lytic Detection System assay as per manufacturer's instructions.

Western blot detection of HBeAg-HiBiT protein

For verification of target identity and degrader activity on target by Western blot, cells were plated at 500 000 per well in a 6-well plate overnight. The next day, 1 $\mu\text{g mL}^{-1}$ final concentration of DOX was added and cells were incubated for 24 h. Degradations were added at the same time as DOX and incubated for another 24 h. After incubation, for HBeAg, supernatant samples were taken before cells were harvested, washed once in ice cold PBS and then lysed in RIPA buffer supplemented with protease/phosphatase inhibitor cocktail (Pierce – HALT cocktail). Lysates were clarified by centrifugation at 21 000 $\times g$ for 20 min at 4 °C and then subjected to a BCA assay to determine protein concentration. 50 μg of each lysate or 20 μL of undilute supernatant mixed with 4 $\times$ LDS reducing sample buffer were then run in MES buffer on 4–12% Bis-Tris SDS-PAGE gels at 150 V for 1 h and transferred to PVDF membranes using an iBlot apparatus at P3 for 7 min. After 1 h of blocking the membrane in Intercept blocking buffer (Licor), membranes were probed with anti-HiBiT mouse monoclonal antibody at 1 $\mu\text{g mL}^{-1}$ (Promega) and with anti-HiBiT tag mouse monoclonal antibody

at 1:2000 (Promega), anti-HBeAg mouse monoclonal antibody at 1:500 (Santa Cruz Biotechnology) or anti-GAPDH rabbit monoclonal antibody at 1:10 000 (Cell Signaling) overnight at 4 °C, all diluted in Intercept buffer + 0.1% Tween-20. After three washes in TBS + 0.1% Tween-20, membranes were probed for 1 h at room temperature with anti-mouse AF680 and anti-rabbit AF800 secondary antibodies (Thermo Fisher) diluted 1:10 000 in Intercept buffer + 0.1% Tween-20 followed by three final washes. Membranes were then scanned on the Odyssey XF infrared scanning system (Licor) for image acquisition.

HepAD38 culture and western blot

HepAD38 cells⁵² (kindly provided by Gilead Sciences USA) were cultured in DMEM/F-12 (ThermoFisher) supplemented with 10% FCS, penicillin/streptomycin (ThermoFisher) and 500 $\mu\text{g mL}^{-1}$ geneticin (ThermoFisher) at 37 °C, 5% CO_2 .

To examine the effect of compound treatment on intracellular core protein levels, HepAD38 cells were seeded into 12-well plates and cultured in the presence of each compound at 10 μM with media replenished at day 3. After 6 days of culture, media was aspirated, cells washed with PBS, and cells lysed in NP40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris, pH 7.5 with protease inhibitor (Pierce)) for 20 min at 4 °C with gentle rocking. Lysates were then clarified at 5000 g for 5 min at 4 °C.

For Western blot analysis, clarified lysates were diluted in Laemmli buffer (Biorad) and boiled for 5 min prior to loading on Mini-PROTEAN TGX Precast Protein Gels (Any kD, Biorad) alongside MagicMark XP Western Protein Standard (ThermoFisher) and electrophoresed using Biorad MINI-Protean electrophoresis apparatus in 1 $\times$ Tris/Glycine/SDS buffer (Biorad). After electrophoresis, samples were transferred onto nitrocellulose membranes using semi-dry transfer apparatus (Biorad Trans Blot Turbo system). Membranes were then blocked overnight in 3% skim milk powder in PBS-Tween (0.1%) at 4 °C. After washing with PBS-Tween (0.1%) at room temp, membranes were probed with primary mouse anti-hepatitis B virus core antigen antibody [C1] (Abcam) at 1:1000 for 3 h, and secondary rabbit anti-mouse-HRP (Sigma) for 1 h, and detection of bands using Western Lightning Plus chemiluminescent substrate (Perkin Elmer) and Biorad ChemiDoc and Image lab software.

Virological HBeAg secretion assay

Huh7 cells (maintained on DMEM + 10% FCS + penicillin/streptomycin) were transfected with 1.3mer hepatitis B virus infectious clones encoding either wildtype HBV (1.3_HBVgenD-wt) or HBV encoding the core_T109I mutation (1.3_HBVgenD_c_T109I), using Eugene 6 Transfection reagent (Promega) according to manufacturer's instructions, and incubated at 37 °C, 5% CO_2 .

At 24 hours post-transfection, cell culture media was removed and replaced with fresh media containing each compound at a final concentration of 10 μM , or vehicle control (DMSO). After a further 24 hours incubation, cell

culture supernatant was collected, and HBeAg quantified using the Diasorin Liaison® diagnostic platform.

Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

There is no conflict of interest to declare.

Acknowledgements

L. T. H. was the recipient of a Research Training Program scholarship from the Australian Government.

References

- WHO, *Global Hepatitis Report 2017*, Geneva, 2017.
- S. K. Fung and A. S. F. Lok, *Nat. Clin. Pract. Gastroenterol. Hepatol.*, 2004, **1**, 90–97.
- U. Viswanathan, N. Mani, Z. Hu, H. Ban, Y. Du, J. Hu, J. Chang and J. T. Guo, *Antiviral Res.*, 2020, **182**, 104917.
- A. Zlotnick, B. Venkatakrishnan, Z. Tan, E. Lewellyn, W. Turner and S. Francis, *Antiviral Res.*, 2015, **121**, 82–93.
- F. Messageot, S. Salhi, P. Eon and J.-M. Rossignol, *J. Biol. Chem.*, 2003, **278**, 891–895.
- X. Hong, L. Luckenbaugh, M. Mendenhall, R. Walsh, L. Cabuang, S. Soppe, P. A. Revill, D. Burdette, B. Feierbach, W. Delaney and J. Hu, *J. Virol.*, 2021, **95**, DOI: [10.1128/jvi.01695-01620](https://doi.org/10.1128/jvi.01695-01620).
- D. Milich and T. J. Liang, *Hepatology*, 2003, **38**, 1075–1086.
- M. A. DiMattia, N. R. Watts, S. J. Stahl, J. M. Grimes, A. C. Steven, D. I. Stuart and P. T. Wingfield, *Structure*, 2013, **21**, 133–142.
- T. Lang, C. Lo, N. Skinner, S. Locarnini, K. Visvanathan and A. Mansell, *J. Hepatol.*, 2011, **55**, 762–769.
- K. Padarath, A. Deroubaix and A. Kramvis, *Viruses*, 2023, **15**, 857.
- M. T. Chen, J.-N. Billaud, M. Sällberg, L. G. Guidotti, F. V. Chisari, J. Jones, J. Hughes and D. R. Milich, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 14913–14918.
- M. Chen, M. Sällberg, J. Hughes, J. Jones, G. Guidotti Luca, V. Chisari Francis, J.-N. Billaud and R. Milich David, *J. Virol.*, 2005, **79**, 3016–3027.
- I. Lazarevic, A. Banko, D. Miljanovic and M. Cupic, *Viruses*, 2019, **11**, 778.
- P. D. Garcia, J. H. Ou, W. J. Rutter and P. Walter, *J. Cell Biol.*, 1988, **106**, 1093–1104.
- X. Hong, N. Bianchini Emily, C.-Y. Wang Joseph and J. Hu, *mBio*, 2023, **14**, e03501–e03522.
- D. R. Milich, *Hum. Vaccines Immunother.*, 2019, **15**, 2187–2191.
- J. Wu, Z. Meng, M. Jiang, R. Pei, M. Trippler, R. Broering, A. Bucchi, J. P. Sowa, U. Dittmer, D. Yang, M. Roggendorf, G. Gerken, M. Lu and J. F. Schlaak, *Hepatology*, 2009, **49**, 1132–1140.
- J. Samal, M. Kandpal and P. Vivekanandan, *Sci. Rep.*, 2017, **7**, 14371.
- A. M. Mohareb, A. F. Liu, A. Y. Kim, P. A. Coffie, M. G. Kouamé, K. A. Freedberg, A. Boyd and E. P. Hyle, *J. Infect. Dis.*, 2022, **226**, 1761–1770.
- P. K. Parikh, N. H. Parikh, B. Mahalakshmi, K. M. Ranch, S. H. S. Boddu, B. R. Jayachandra and A. K. Tiwari, *Arab. J. Chem.*, 2023, **16**, 105013.
- C. R. Bourne, M. G. Finn and A. Zlotnick, *J. Virol.*, 2006, **80**, 11055–11061.
- C. Bourne, S. Lee, B. Venkataiah, A. Lee, B. Korba, M. G. Finn and A. Zlotnick, *J. Virol.*, 2008, **82**, 10262–10270.
- J. Lin, L. Yin, X.-Z. Xu, H.-C. Sun, Z.-H. Huang, X.-Y. Ni, Y. Chen and X. Lin, *PLoS Pathog.*, 2022, **18**, e1010204.
- Z. Yan, D. Wu, H. Hu, J. Zeng, X. Yu, Z. Xu, Z. Zhou, X. Zhou, G. Yang, J. A. T. Young and L. Gao, *Hepatology*, 2019, **70**, 11–24.
- M. Békés, D. R. Langley and C. M. Crews, *Nat. Rev. Drug Discovery*, 2022, **21**, 181–200.
- G. Dong, Y. Ding, S. He and C. Sheng, *J. Med. Chem.*, 2021, **64**, 10606–10620.
- J. M. Tsai, R. P. Nowak, B. L. Ebert and E. S. Fischer, *Nat. Rev. Mol. Cell Biol.*, 2024, **25**, 740–757.
- S. Xie, J. Zhu, J. Li, F. Zhan, H. Yao, J. Xu and S. Xu, *J. Med. Chem.*, 2023, **66**, 10917–10933.
- A. Chakravarty and P. L. Yang, *Antiviral Res.*, 2023, **210**, 105480.
- Y. R. Alugubelli, J. Xiao, K. Khatua, S. Kumar, L. Sun, Y. Ma, X. R. Ma, V. R. Vulupala, S. Atla, L. R. Blankenship, D. Coleman, X. Xie, B. W. Neuman, W. R. Liu and S. Xu, *J. Med. Chem.*, 2024, **67**, 6495–6507.
- M. de Wispelaere, G. Du, K. A. Donovan, T. Zhang, N. A. Eleuteri, J. C. Yuan, J. Kalabathula, R. P. Nowak, E. S. Fischer, N. S. Gray and P. L. Yang, *Nat. Commun.*, 2019, **10**, 3468.
- Z. Xu, X. Liu, X. Ma, W. Zou, Q. Chen, F. Chen, X. Deng, J. Liang, C. Dong, K. Lan, S. Wu and H.-B. Zhou, *Cell Insight*, 2022, **1**, 100030.
- S. Cheng, Y. Feng, W. Li, T. Liu, X. Lv, X. Tong, G. Xi, X. Ye and X. Li, *Eur. J. Med. Chem.*, 2024, **275**, 116629.
- Z. Li, H.-Y. Liu, Z. He, A. Chakravarty, R. P. Golden, Z. Jiang, I. You, H. Yue, K. A. Donovan, G. Du, J. Che, J. Tse, I. Che, W. Lu, E. S. Fischer, T. Zhang, N. S. Gray and P. L. Yang, *bioRxiv*, 2024, preprint, DOI: [10.1101/2024.06.01.596987](https://doi.org/10.1101/2024.06.01.596987).
- K. Klumpp, A. M. Lam, C. Lukacs, R. Vogel, S. Ren, C. Espiritu, R. Baydo, K. Atkins, J. Abendroth, G. Liao, A. Efimov, G. Hartman and O. A. Flores, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 15196.
- S. Nair, L. Li, S. Francis, W. W. Turner, M. VanNieuwenhze and A. Zlotnick, *J. Am. Chem. Soc.*, 2018, **140**, 15261–15269.
- W. Zhang, L. Guo, H. Liu, G. Wu, H. Shi, M. Zhou, Z. Zhang, B. Kou, T. Hu, Z. Zhou, Z. Xu, X. Zhou, Y. Zhou, X. Tian, G. Yang, J. A. T. Young, H. Qiu, G. Ottaviani, J. Xie, A. V. Mayweg, H. C. Shen and W. Zhu, *J. Med. Chem.*, 2023, **66**, 4253–4270.
- Z. Qiu, X. Lin, W. Zhang, M. Zhou, L. Guo, B. Kocer, G. Wu, Z. Zhang, H. Liu, H. Shi, B. Kou, T. Hu, Y. Hu, M. Huang,

- S. F. Yan, Z. Xu, Z. Zhou, N. Qin, Y. F. Wang, S. Ren, H. Qiu, Y. Zhang, Y. Zhang, X. Wu, K. Sun, S. Zhong, J. Xie, G. Ottaviani, Y. Zhou, L. Zhu, X. Tian, L. Shi, F. Shen, Y. Mao, X. Zhou, L. Gao, J. A. T. Young, J. Z. Wu, G. Yang, A. V. Mayweg, H. C. Shen, G. Tang and W. Zhu, *J. Med. Chem.*, 2017, **60**, 3352–3371.
- 39 M. K. Schwinn, T. Machleidt, K. Zimmerman, C. T. Eggers, A. S. Dixon, R. Hurst, M. P. Hall, L. P. Encell, B. F. Binkowski and K. V. Wood, *ACS Chem. Biol.*, 2018, **13**, 467–474.
- 40 K. M. Riching, S. Mahan, C. R. Corona, M. McDougall, J. D. Vasta, M. B. Robers, M. Urh and D. L. Daniels, *ACS Chem. Biol.*, 2018, **13**, 2758–2770.
- 41 K. M. Riching, S. D. Mahan, M. Urh and D. L. Daniels, High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines, 1940-087X, 2020.
- 42 B. Pan, S. Mountford, M. Kiso, D. Anderson, G. Papadakis, K. Jarman, D. Tilmais, B. Maher, T. Tran, J. Shortt, S. Yamayoshi, Y. Kawaoka, P. Thompson, S. Greenall and N. Warner, *Research Square*, 2024, DOI: [10.21203/rs.3.rs-3932156/v1](https://doi.org/10.21203/rs.3.rs-3932156/v1).
- 43 L. T. Hales and P. E. Thompson, *Chem. – Eur. J.*, 2023, **29**, e202301975.
- 44 A. Daina, O. Michielin and V. Zoete, *Sci. Rep.*, 2017, **7**, 42717.
- 45 A. D. Huber, D. L. Pineda, D. Liu, K. N. Boschert, A. T. Gres, J. J. Wolf, E. M. Coonrod, J. Tang, T. G. Laughlin, Q. Yang, M. N. Puray-Chavez, J. Ji, K. Singh, K. A. Kirby, Z. Wang and S. G. Sarafianos, *ACS Infect. Dis.*, 2019, **5**, 750–758.
- 46 O. Hsia, M. Hinterndorfer, A. D. Cowan, K. Iso, T. Ishida, R. Sundaramoorthy, M. A. Nakasone, H. Imrichova, C. Schätz, A. Rukavina, K. Husnjak, M. Wegner, A. Correa-Sáez, C. Craighon, R. Casement, C. Maniaci, A. Testa, M. Kaulich, I. Dikic, G. E. Winter and A. Ciulli, *Nature*, 2024, **627**, 204–211.
- 47 V. Vetma, L. C. Perez, J. Eliaš, A. Stinga, A. Kombara, T. Gmaschitz, N. Braun, T. Ciftci, G. Dahmann, E. Diers, T. Gerstberger, P. Greb, G. Kidd, C. Kofink, I. Puoti, V. Spiteri, N. Trainor, H. Weinstabl, Y. Westermaier, C. Whitworth, A. Ciulli, W. Farnaby, K. McAulay, A. B. Frost, N. Chessum and M. Koegl, *ACS Chem. Biol.*, 2024, **19**, 1484–1494.
- 48 T. Shoda, N. Ohoka, G. Tsuji, T. Fujisato, H. Inoue, Y. Demizu, M. Naito and M. Kurihara, *Pharmaceuticals*, 2020, **13**, 34.
- 49 X. Qu, H. Liu, X. Song, N. Sun, H. Zhong, X. Qiu, X. Yang and B. Jiang, *Eur. J. Med. Chem.*, 2021, **218**, 113328.
- 50 Y.-Q. Li, W. G. Lannigan, S. Davoodi, F. Daryaei, A. Corriero, P. Alfonso, J. A. Rodriguez-Santamaria, N. Wang, J. D. Haley and P. J. Tonge, *J. Med. Chem.*, 2023, **66**, 7454–7474.
- 51 D. P. Bondeson, A. Mares, I. E. D. Smith, E. Ko, S. Campos, A. H. Miah, K. E. Mulholland, N. Routly, D. L. Buckley, J. L. Gustafson, N. Zinn, P. Grandi, S. Shimamura, G. Bergamini, M. Faelt-Savitski, M. Bantscheff, C. Cox, D. A. Gordon, R. R. Willard, J. J. Flanagan, L. N. Casillas, B. J. Votta, W. den Besten, K. Famm, L. Kruidenier, P. S. Carter, J. D. Harling, I. Churcher and C. M. Crews, *Nat. Chem. Biol.*, 2015, **11**, 611–617.
- 52 S. K. Ladner, M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang, J. T. Guo, C. Seeger and R. W. King, *Antimicrob. Agents Chemother.*, 1997, **41**, 1715–1720.